Share ownership Laboratorios Farmaceuticos Rovi, S.A. OTC Markets
Stocks
LABFF
ES0157261019
Pharmaceuticals
|
Market Closed -
OTC Markets
07:00:03 03/08/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 67.17 USD | +1.98% |
|
0.00% | +1.98% |
| 23/07 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 | |
| 23/07 | Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
Share class: Laboratorios Farmaceuticos Rovi, S.A.
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 5,12,35,762 | 1,62,08,105 ( 31.63 %) | 92,764 ( 0.1811 %) | 31.63 % |
Major shareholders: Laboratorios Farmaceuticos Rovi, S.A.
| Name | Stocks | % | Valuation |
|---|---|---|---|
Norbel Inversiones SL
58.19
%
| 2,98,12,040 | 58.19 % | 2 008 M $ |
Indumenta Pueri SL
10.01
%
| 51,26,303 | 10.01 % | 345 M $ |
Santander Private Banking Gestion SA SGIIC
1.14
%
| 5,84,258 | 1.14 % | 39 M $ |
Invesco Asset Management Ltd.
0.959
%
| 4,91,351 | 0.959 % | 33 M $ |
Shareholder Value Management AG
0.8632
%
| 4,42,243 | 0.8632 % | 30 M $ |
Muza Gestion de Activos SGIIC SA
0.6968
%
| 3,56,992 | 0.6968 % | 24 M $ |
BN & Partners Capital AG
0.6914
%
| 3,54,236 | 0.6914 % | 24 M $ |
Financière de l'Échiquier SA
0.5994
%
| 3,07,085 | 0.5994 % | 21 M $ |
Bestinver Gestión SA SGIIC
0.5136
%
| 2,63,160 | 0.5136 % | 18 M $ |
Bankinter Gestión de Activos SA SGIIC
0.4085
%
| 2,09,297 | 0.4085 % | 14 M $ |
░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
Breakdown by shareholder type
| Others | 68.19% |
| Institutional | 9.69% |
| Laboratorios Farmaceúticos Rovi SA | 0.17% |
| Unknown | 21.95% |
Based on 1000 largest holdings
Geographical origin of shareholders
Spain | 73.73% |
Germany | 1.73% |
United Kingdom | 1.11% |
France | 0.79% |
Netherlands | 0.22% |
Italy | 0.17% |
Finland | 0.16% |
Luxembourg | 0.1% |
United States | 0.01% |
Belgium | 0.01% |
Malta | 0.01% |
Switzerland | 0.01% |
Based on 1000 largest holdings
Employees
2,470
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
















